Traws Pharma Inc
TRAW
View Detailed Chart
2.030USD
-0.030-1.46%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
14.35MMarket Cap
0.16P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.46%
5 Days
+6.28%
1 Month
+51.49%
6 Months
-26.71%
Year to Date
-77.14%
1 Year
-73.81%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
150.000
Target Price
+4185.71%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Growing
The company is in a growing phase, with the latest annual income totaling USD 226.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 188.30.
Overvalued
The company’s latest PE is 0.02, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 2.78M shares, increasing 3.21% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 13.17K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Ticker SymbolTRAW
CompanyTraws Pharma Inc
CEODr. Iain D. Dukes, Ph.D.
Websitehttps://www.onconova.com/
Related Instruments
+0.68%
+1.38%
-2.48%
-1.57%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.44%
-0.19%
-1.18%
-2.84%
0.00%
+0.30%
-3.72%
